Cargando…
Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC)
BACKGROUND: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal tra...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898115/ https://www.ncbi.nlm.nih.gov/pubmed/24330423 http://dx.doi.org/10.1186/1479-5876-11-311 |
_version_ | 1782300363076927488 |
---|---|
author | Karamitopoulou, Eva Zlobec, Inti Gloor, Beat Kondi-Pafiti, Agathi Lugli, Alessandro Perren, Aurel |
author_facet | Karamitopoulou, Eva Zlobec, Inti Gloor, Beat Kondi-Pafiti, Agathi Lugli, Alessandro Perren, Aurel |
author_sort | Karamitopoulou, Eva |
collection | PubMed |
description | BACKGROUND: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal transition (EMT). The aim of this study was to evaluate RKIP expression and to determine its association with clinicopathological features, including EMT in form of tumor budding in pancreatic ductal adenocarcinoma (PDAC). METHODS: Staining for RKIP was performed on a multipunch Tissue Microarray (TMA) of 114 well-characterized PDACs with clinico-pathological, follow-up and adjuvant therapy information. RKIP-expression was assessed separately in the main tumor body and in the tumor buds. Another 3 TMAs containing normal pancreatic tissue, precursor lesions (Pancreatic Intraepithelial Neoplasia, PanINs) and matched lymph node metastases were stained in parallel. Cut-off values were calculated by receiver operating characteristic (ROC) curve analysis. RESULTS: We found a significant progressive loss of RKIP expression between normal pancreatic ductal epithelia (average: 74%), precursor lesions (PanINs; average: 37%), PDAC (average 20%) and lymph node metastases (average 8%, p < 0.0001). RKIP expression was significantly lower in tumor buds (average: 6%) compared to the main tumor body (average 20%; p < 0.005). RKIP loss in the tumor body was marginally associated with advanced T-stage (p = 0.0599) as well as high-grade peritumoral (p = 0.0048) and intratumoral budding (p = 0.0373). RKIP loss in the buds showed a clear association with advanced T stage (p = 0.0089). CONCLUSIONS: The progressive loss of RKIP seems to play a major role in the neoplastic transformation of pancreas, correlates with aggressive features in PDAC and is associated with the presence of EMT in form of tumor budding. |
format | Online Article Text |
id | pubmed-3898115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38981152014-01-23 Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) Karamitopoulou, Eva Zlobec, Inti Gloor, Beat Kondi-Pafiti, Agathi Lugli, Alessandro Perren, Aurel J Transl Med Research BACKGROUND: Raf-1 kinase inhibitor protein (RKIP) has emerged as a significant metastatic suppressor in a variety of human cancers and is known to inhibit Ras/Raf/MEK/ERK signaling. By suppressing the activation of the NFkB/SNAIL circuit, RKIP can regulate the induction of epithelial-mesenchymal transition (EMT). The aim of this study was to evaluate RKIP expression and to determine its association with clinicopathological features, including EMT in form of tumor budding in pancreatic ductal adenocarcinoma (PDAC). METHODS: Staining for RKIP was performed on a multipunch Tissue Microarray (TMA) of 114 well-characterized PDACs with clinico-pathological, follow-up and adjuvant therapy information. RKIP-expression was assessed separately in the main tumor body and in the tumor buds. Another 3 TMAs containing normal pancreatic tissue, precursor lesions (Pancreatic Intraepithelial Neoplasia, PanINs) and matched lymph node metastases were stained in parallel. Cut-off values were calculated by receiver operating characteristic (ROC) curve analysis. RESULTS: We found a significant progressive loss of RKIP expression between normal pancreatic ductal epithelia (average: 74%), precursor lesions (PanINs; average: 37%), PDAC (average 20%) and lymph node metastases (average 8%, p < 0.0001). RKIP expression was significantly lower in tumor buds (average: 6%) compared to the main tumor body (average 20%; p < 0.005). RKIP loss in the tumor body was marginally associated with advanced T-stage (p = 0.0599) as well as high-grade peritumoral (p = 0.0048) and intratumoral budding (p = 0.0373). RKIP loss in the buds showed a clear association with advanced T stage (p = 0.0089). CONCLUSIONS: The progressive loss of RKIP seems to play a major role in the neoplastic transformation of pancreas, correlates with aggressive features in PDAC and is associated with the presence of EMT in form of tumor budding. BioMed Central 2013-12-14 /pmc/articles/PMC3898115/ /pubmed/24330423 http://dx.doi.org/10.1186/1479-5876-11-311 Text en Copyright © 2013 Karamitopoulou et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Karamitopoulou, Eva Zlobec, Inti Gloor, Beat Kondi-Pafiti, Agathi Lugli, Alessandro Perren, Aurel Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) |
title | Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) |
title_full | Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) |
title_fullStr | Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) |
title_full_unstemmed | Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) |
title_short | Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) |
title_sort | loss of raf-1 kinase inhibitor protein (rkip) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (pdac) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898115/ https://www.ncbi.nlm.nih.gov/pubmed/24330423 http://dx.doi.org/10.1186/1479-5876-11-311 |
work_keys_str_mv | AT karamitopouloueva lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac AT zlobecinti lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac AT gloorbeat lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac AT kondipafitiagathi lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac AT luglialessandro lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac AT perrenaurel lossofraf1kinaseinhibitorproteinrkipisstronglyassociatedwithhighgradetumorbuddingandcorrelateswithanaggressivephenotypeinpancreaticductaladenocarcinomapdac |